| 1 | Baseline disease modifying therapies (DMTs) | - | - | - | - | 1件: 13 13 |
| 2 | BG00012 (DMF) | - | - | - | - | 1件: 13 13 |
| 3 | BG00012 (DMF) (Tecfidera®.) | - | - | - | - | 1件: 13 13 |
| 4 | Biologic DMARD | - | - | - | - | 2件: 46 46, 271 |
| 5 | Biologic DMARDs | - | - | - | - | 1件: 107 107 |
| 6 | Biological DMARDs | - | - | - | - | 2件: 86 86, 107 |
| 7 | Classic DMARDs treatment group | - | - | - | - | 1件: 46 46 |
| 8 | Co-medication: Synthetic DMARDs | - | - | - | - | 1件: 46 46 |
| 9 | Combination of DMARDs | - | - | - | - | 1件: 107 107 |
| 10 | Conventional DMARD combination | - | - | - | - | 1件: 46 46 |
| 11 | Conventional DMARDs | - | - | - | - | 1件: 46 46 |
| 12 | Conventional Synthetic DMARD | - | - | - | - | 1件: 46 46 |
| 13 | CP-690-550-10 (DMID D1600180) | - | - | - | - | 1件: 107 107 |
| 14 | Daunorubicin
(Synonym: DM) | 1件: Daunorubicin Daunorubicin | 1件: D07776
D07776
(Name: DM) | 2件: TOP2A TOP2A,
TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 65 65 |
| 15 | Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg) | 2件: Dextromethorphan Dextromethorphan (Synonym: Good Sense Cough DM),
Quinidine | 2件: D03742
D03742
,
D08458
| 11件: GRIN1 GRIN1,
GRIN2A,
GRIN2B,
GRIN2C,
GRIN2D,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SIGMAR1 💬 | 22件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, Taste transduction, cAMP signaling pathway 💬 | 1件: 8 8 |
| 16 | Dimethyl Fumarate (DMF) | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 3件: 13 13, 51, 86 |
| 17 | Dimethyl fumarate [DMF] | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
| 18 | Dimethyl sulfoxide (DMSO) | 1件: Dimethyl sulfoxide Dimethyl sulfoxide (Synonym: DMSO) | 1件: D01043
D01043
| - | - | 1件: 226 226 |
| 19 | Disease modifying treatment (DMT) | - | - | - | - | 1件: 13 13 |
| 20 | Disease-modifying antirheumatic drugs (DMARDs) | - | - | - | - | 1件: 46 46 |
| 21 | DM | - | - | - | - | 2件: 6 6, 8 |
| 22 | DM-1992 | - | - | - | - | 1件: 6 6 |
| 23 | DMARD | - | - | - | - | 1件: 46 46 |
| 24 | DMARD cessation | - | - | - | - | 1件: 46 46 |
| 25 | DMARD maintenance | - | - | - | - | 1件: 46 46 |
| 26 | DMARD Therapy | - | - | - | - | 1件: 46 46 |
| 27 | DMARDS | - | - | - | - | 2件: 46 46, 271 |
| 28 | DMARDs (disease-modifying antirheumatic drugs) | - | - | - | - | 1件: 46 46 |
| 29 | DMARDs (methotrexate | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR,
DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
| 30 | DMARDs or Biologics | - | - | - | - | 1件: 46 46 |
| 31 | DMPS | 1件: 2,3-Dimercapto-1-propanesulfonic acid 2,3-Dimercapto-1-propanesulfonic acid (Synonym: DMPS) | - | - | - | 1件: 171 171 |
| 32 | DMSA | 1件: Succimer Succimer (Synonym: DMSA) | 1件: D00572
D00572
| - | - | 1件: 171 171 |
| 33 | DMSO | 1件: Dimethyl sulfoxide Dimethyl sulfoxide (Synonym: DMSO) | 1件: D01043
D01043
| - | - | 1件: 226 226 |
| 34 | DMSO cocktail | 1件: Dimethyl sulfoxide Dimethyl sulfoxide (Synonym: DMSO) | 1件: D01043
D01043
| - | - | 1件: 226 226 |
| 35 | DMT | - | - | - | - | 1件: 13 13 |
| 36 | DMT continuation | - | - | - | - | 1件: 13 13 |
| 37 | DMX-200 | - | - | - | - | 1件: 222 222 |
| 38 | Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA,
TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
| 39 | Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS | - | - | - | - | 1件: 13 13 |
| 40 | First line DMT | - | - | - | - | 1件: 13 13 |
| 41 | HUC-MSC + DMARDs | - | - | - | - | 1件: 46 46 |
| 42 | Injectable MS DMT | - | - | - | - | 1件: 13 13 |
| 43 | IONIS-DMPKRx | - | - | - | - | 1件: 113 113 |
| 44 | Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD) | - | - | - | - | 1件: 46 46 |
| 45 | Non-Biologic DMARDs | - | - | - | - | 3件: 46 46, 86, 107 |
| 46 | Non-biological DMARDs | - | - | - | - | 1件: 46 46 |
| 47 | Nonbiologic DMARDs of investigator's choice | - | - | - | - | 1件: 46 46 |
| 48 | Patient treated with DMARD | - | - | - | - | 1件: 46 46 |
| 49 | Permitted DMARDs | - | - | - | - | 1件: 46 46 |
| 50 | Phase 1: Conventiaonal DMARD | - | - | - | - | 1件: 46 46 |
| 51 | Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs) | - | - | - | - | 1件: 46 46 |
| 52 | Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | - | - | - | - | 1件: 46 46 |
| 53 | Standard MS DMT | - | - | - | - | 1件: 13 13 |
| 54 | Standard MS DMTs | - | - | - | - | 1件: 13 13 |
| 55 | Synthetic DMARD(s) | - | - | - | - | 1件: 46 46 |
| 56 | Targeted synthetic DMARD class | - | - | - | - | 1件: 46 46 |
| 57 | Therapy with disease-modifying anti rheumatic drugs (DMARD) | - | - | - | - | 1件: 46 46 |
| 58 | TNF-a antagonists, non-TNFs, DMARD non-biologics | - | - | - | - | 2件: 46 46, 271 |
| 59 | Trivalent chromium versus synthetic and/ or biological DMARDs | 1件: Chromium Chromium | - | - | - | 1件: 46 46 |
| 60 | UC-MSC+DMARDS | - | - | - | - | 1件: 46 46 |
| 61 | Vinblastine, vincristine, prednisone, daunorubicin
(Synonym: DM) | 4件: Daunorubicin Daunorubicin,
Prednisone,
Vinblastine,
Vincristine | 4件: D00473
D00473
,
D07776
(Name: DM),
D08675
,
D08679
| 12件: NR3C1 NR3C1,
TOP2A,
TOP2B,
TUBB,
TUBB1,
TUBB2A,
TUBB2B,
TUBB3,
TUBB4A,
TUBB4B,
TUBB6,
TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬 | 1件: 65 65 |